IGFBP-3 Protein, Cynomolgus, Recombinant (His Tag)

CAT:
882-PK54149M1
Size:
100 µg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
IGFBP-3 Protein, Cynomolgus, Recombinant (His Tag) - image 1

IGFBP-3 Protein, Cynomolgus, Recombinant (His Tag)

  • Background:

    The Insulin-like Growth Factor (IGF) signaling system plays a central role in cellular growth, differentiation, and proliferation. IGFBP3 is the most abundant IGF binding protein in human serum and is a growth inhibitory, apoptosis-inducing molecule, capable of acting via IGF-dependent and IGF-independent mechanisms. It appears to function both by cell cycle blockade and the induction of apoptosis. IGFBP3 can be transported to the nucleus by an importin beta mediated mechanism, where it has been shown to interact with the retinoid X receptor alpha and possibly other nuclear elements. IGFBP3 antiproliferative signaling appears to require an active transforming growth factor-beta (TGF-beta) signaling pathway, and IGFBP3 stimulates phosphorylation of the TGF-beta signaling intermediates Smad2 and Smad3. IGFBP3 has IGF-independent roles in inhibiting cell proliferation in cancer cell lines. Nuclear transcription factor, retinoid X receptor (RXR) -alpha, and IGFBP3 functionally interact to reduce prostate tumor growth and prostate-specific antigen in vivo. Several clinical studies have proposed that individuals with IGFBP3 levels in the upper range of normal may have a decreased risk for certain common cancers. This includes evidence of a protective effect against breast cancer, prostate cancer, colorectal cancer, and lung cancer. Moreover, IGFBP3 inhibits insulin-stimulated glucose uptake into adipocytes independent of IGF.
  • Gene Name:

    Insulin-like growth factor binding protein 3
  • Expression System:

    HEK293 Cells
  • Tag:

    N-His
  • Endotoxin:

    < 1.0 EU per μg of the protein as determined by the LAL method.
  • Purity:

    > 95 % as determined by SDS-PAGE.
  • Activity:

    Measured by its ability to inhibit the biological activity of IGFII on MCF7 human breast adenocarcinoma cells (Karey, K.P. et al. (1988) Cancer Research 48:4083.) .The EDfor this effect is typically 0.15-0.75 μg/mL in the presence of 14 ng/mL human IGFII.
  • Form:

    Lyophilized
  • Buffer:

    Lyophilized from sterile PBS, pH 7.4. Please contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the hard copy of CoA.
  • Function:

    Diagnostic proteins, Growth Factor proteins, Biomarker Proteins
  • Molecular Weight:

    The recombinant heterodimer of cynomolgus IGFBP3 comprises 284 amino acids and has a calculated molecular mass of 31.1 KDa. The apparent molecular mass of the protein is approximately 41-44 KDa respectively in SDS-PAGE.
  • Storage Conditions:

    In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature. Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise. Stable for 1 year at -20°C or below from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and opening the cap. For long-term storage, aliquot and store at -20°C or below. Avoid repeated freeze-thaw cycles.
  • Symbol:

    IGFBP3
  • Species:

    Cynomolgus
  • Overview:

    A DNA sequence encoding the cynomolgus IGFBP3 (Gly28-Lys291) was expressed with a polyhistide tag at the N-terminus.
  • AA Sequence:

    Gly28-Lys291